Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen(University of Southern California), Simon P. Langdon(Edinburgh Cancer Research)
Cited by 55
Related Papers
SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition
|Nature Communications|2021|152
Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment
|BMC Cancer|2018|107
Evaluation of carbonic anhydrase IX as a therapeutic target for inhibition of breast cancer invasion and metastasis using a series of<i>in vitro</i>breast cancer models
|Oncotarget|2015|96
HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer
|Breast Cancer Research|2019|69
Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
|British Journal of Cancer|2012|49